

# Javier GarcÃ-a-Samaniego

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7168646/publications.pdf>

Version: 2024-02-01

139  
papers

9,030  
citations

66336

42  
h-index

42393

92  
g-index

153  
all docs

153  
docs citations

153  
times ranked

8886  
citing authors

#	ARTICLE	IF	CITATIONS
1	A cascade of care analysis on the elimination of hepatitis C from public hospitals in Madrid. <i>Communications Medicine</i> , 2022, 2, .	4.2	2
2	Mild ast elevation as an early sign of COVID-19 severity in a multicenter Madrid cohort. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, 113, 780-786.	0.3	2
3	Hepatitis C reflex testing in Spain in 2019: A story of success. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed )</i> , 2021, 39, 119-126.	0.3	0
4	Diagnóstico en un solo paso de la hepatitis C en 2019: una realidad en España. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2021, 39, 119-126.	0.5	15
5	Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects. <i>Liver International</i> , 2021, 41, 2076-2086.	3.9	13
6	One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 462-469.	3.7	25
7	Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. <i>Scientific Reports</i> , 2021, 11, 24133.	3.3	13
8	Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5.	4.4	104
9	Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 158-166.	3.7	49
10	A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. <i>Journal of Hepatology</i> , 2020, 72, 816-827.	3.7	165
11	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	4.1	39
12	SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain. <i>Journal of Hepatology</i> , 2020, 73, 1262-1263.	3.7	24
13	Documento de consenso de la Asociación Española para el Estudio del Hígado sobre el tratamiento de la infección por el virus de la hepatitis B (2020). <i>Gastroenterología Y Hepatología</i> , 2020, 43, 559-587.	0.5	18
14	Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19. <i>Journal of Infectious Diseases</i> , 2020, 222, 726-733.	4.0	43
15	Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. <i>Journal of Hepatology</i> , 2020, 73, 17-25.	3.7	59
16	Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2020, 43, 559-587.	0.1	20
17	Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). <i>Gastroenterología Y Hepatología (English Edition)</i> , 2019, 42, 579-592.	0.1	2
18	Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice—the Vie-KinD study. <i>PLoS ONE</i> , 2019, 14, e0221567.	2.5	7

#	ARTICLE	IF	CITATIONS
19	Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. <i>Journal of Hepatology</i> , 2019, 71, 666-672.	3.7	67
20	HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz214.	0.9	4
21	Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2019, 37, 222-230.	0.3	0
22	Hepatitis C prevalence among the migrant population in Spain: A systematic review and meta-analysis. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 222-230.	0.5	16
23	Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA real-world cohort. <i>Journal of Viral Hepatitis</i> , 2019, 26, 55-64.	2.0	20
24	Eliminación de la hepatitis C. Documento de posicionamiento de la Asociación Española para el Estudio del Hígado (AEEH). <i>Gastroenterología Y Hepatología</i> , 2019, 42, 579-592.	0.5	25
25	Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment. <i>World Journal of Gastroenterology</i> , 2019, 25, 5883-5896.	3.3	6
26	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	8.1	1,241
27	According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1 <sup>low</sup> HCV-Specific CD8 <sup>+</sup> Cell Reactivity. <i>Journal of Virology</i> , 2018, 92, .	3.4	18
28	The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1260-1270.	3.7	70
29	Expression of PD-1 and Tim-3 markers of T-cell exhaustion is associated with CD4 dynamics during the course of untreated and treated HIV infection. <i>PLoS ONE</i> , 2018, 13, e0193829.	2.5	31
30	Hepatitis E virus in neurological disorders: a case of Parsonage-Turner syndrome. <i>Revista Española De Enfermedades Digestivas</i> , 2018, 110, 402-403.	0.3	3
31	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	8.1	1,619
32	Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 784-793.	2.3	55
33	Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 945-949.e1.	4.4	22
34	Eliminación de la hepatitis C en España: adaptación de un modelo matemático de salud pública partiendo del plan estratégico para el abordaje de la hepatitis C en el Sistema Nacional de Salud. <i>Medicina Clínica</i> , 2017, 148, 277-282.	0.6	24
35	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa registry. <i>Hepatology</i> , 2017, 65, 1810-1822.	7.3	78
36	Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. <i>Journal of Hepatology</i> , 2017, 66, 1138-1148.	3.7	159

#	ARTICLE	IF	CITATIONS
37	Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection. <i>Aids</i> , 2017, 31, 1253-1260.	2.2	30
38	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017, 37, 1823-1832.	3.9	10
39	Both Hepatitis C Virus-Specific T Cell Responses and IL28B Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C. <i>Journal of Interferon and Cytokine Research</i> , 2017, 37, 278-286.	1.2	1
40	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	8.1	208
41	HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells. <i>PLoS ONE</i> , 2017, 12, e0173943.	2.5	17
42	Hepatitis B and D viruses replication interference: Influence of hepatitis B genotype. <i>World Journal of Gastroenterology</i> , 2016, 22, 3165.	3.3	12
43	HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. <i>PLoS ONE</i> , 2016, 11, e0168544.	2.5	2
44	Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 779-789.	2.2	25
45	Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study. <i>PLoS ONE</i> , 2015, 10, e0122613.	2.5	2
46	High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain. <i>Annals of Hepatology</i> , 2015, 14, 477-486.	1.5	1
47	Hepatitis C virus-mediated Aurora B kinase inhibition modulates inflammatory pathway and viral infectivity. <i>Journal of Hepatology</i> , 2015, 63, 312-319.	3.7	17
48	Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 46-54.	1.6	4
49	High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods. <i>Journal of Clinical Microbiology</i> , 2015, 53, 219-226.	3.9	74
50	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C. <i>Annals of Hepatology</i> , 2014, 13, 356-363.	1.5	18
51	Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease. <i>European Journal of Clinical Investigation</i> , 2014, 44, 65-73.	3.4	49
52	Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain. <i>Gastroenterology &amp; Hepatology</i> , 2013, 36, 555-564.	0.5	1
53	Factors associated with early virological response to peginterferon-2a/ribavirin in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2013, 19, 1943.	3.3	10
54	Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 535-542.	1.6	25

#	ARTICLE	IF	CITATIONS
55	Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1705-1710.	2.8	0
56	Acute hepatitis C in Spain: a retrospective study of 131 cases. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012, 104, 21-28.	0.3	11
57	Pathogenesis of occult chronic hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2011, 17, 1543.	3.3	29
58	Response to: "Is the Study Power Enough to Say "No Difference"?" by Geib et al. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, e37-e38.	2.1	0
59	Elevated TGF- $\beta$ 1 levels might protect HCV/HIV-coinfected patients from liver fibrosis. <i>European Journal of Clinical Investigation</i> , 2011, 41, 70-76.	3.4	21
60	Detection of hepatitis B virus genotype A3 and primary drug resistance mutations in African immigrants with chronic hepatitis B in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 641-644.	3.0	15
61	HCV-Specific T-Cell Responses in HIV/Hepatitis C Virus-Coinfected Patients on Highly Active Antiretroviral Therapy Are Comparable to Those Observed in Hepatitis C Virus-Monoinfected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 1-8.	2.1	21
62	Clinical significance of occult hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2011, 17, 1549.	3.3	19
63	Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related Cirrhosis: Outcomes and Factors Predicting Response. <i>American Journal of Gastroenterology</i> , 2010, 105, 2164-2172.	0.4	62
64	Liver Complications Have Reached a Plateau as Cause of Hospital Admission and Death in HIV Patients in Madrid. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 383-385.	1.1	9
65	Rate and Timing of Hepatitis C Virus Relapse after a Successful Course of Pegylated Interferon plus Ribavirin in HIV-Infected and HIV-Uninfected Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 1397-1401.	5.8	35
66	Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. <i>Hepatology</i> , 2009, 50, 1702-1708.	7.3	136
67	Level, phenotype and activation status of CD4+FoxP3+regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus. <i>Clinical and Experimental Immunology</i> , 2009, 155, 35-43.	2.6	46
68	Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. <i>Journal of Viral Hepatitis</i> , 2009, 16, 790-795.	2.0	35
69	Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. <i>Journal of Viral Hepatitis</i> , 2009, 16, 895-896.	2.0	49
70	Accuracy of Simple Biochemical Tests in Identifying Liver Fibrosis in Patients Co-Infected With Human Immunodeficiency Virus and Hepatitis C Virus. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 339-345.	4.4	36
71	Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. <i>Antiviral Therapy</i> , 2009, 14, 23-32.	1.0	66
72	Liver cirrhosis in HIV-Infected patients: prevalence, aetiology and clinical outcome. <i>Journal of Viral Hepatitis</i> , 2008, 15, 165-172.	2.0	94

#	ARTICLE	IF	CITATIONS
73	Management of hepatitis B virus co-infection on and off antiretroviral therapy. <i>Current HIV/AIDS Reports</i> , 2008, 5, 86-93.	3.1	9
74	Emerging drugs for hepatitis C. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 1-19.	2.4	41
75	Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. <i>Journal of Viral Hepatitis</i> , 2008, 15, 363-369.	2.0	24
76	Response to pegylated interferon plus ribavirin in HIV-coinfected patients with chronic hepatitis C due to genotype 4. <i>Journal of Viral Hepatitis</i> , 2008, 15, 710-715.	2.0	15
77	Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 626-627.	3.0	18
78	Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. <i>Aids</i> , 2008, 22, 15-21.	2.2	57
79	The implications of antiviral drugs with activity against hepatitis B virus and HIV. <i>Current Opinion in Internal Medicine</i> , 2008, 7, 57-64.	1.5	3
80	Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?. <i>Antiviral Therapy</i> , 2008, 13, 97-102.	1.0	23
81	Does Treatment of Hepatitis B virus (HBV) Infection Reduce Hepatitis Delta virus (HDV) Replication in HIV-HBV-HDV-Coinfected Patients?. <i>Antiviral Therapy</i> , 2008, 13, 97-102.	1.0	76
82	Antiretroviral-Associated Portal Hypertension: A New Clinical Condition? Prevalence, Predictors and Outcome. <i>Antiviral Therapy</i> , 2008, 13, 103-108.	1.0	80
83	Hepatitis B Virus Genotypes and Lamivudine Resistance Mutations in HIV/Hepatitis B Virus-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 557-561.	2.1	53
84	Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 972-982.	1.1	183
85	Management and therapy of chronic hepatitis C in HIV. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 482-488.	3.8	1
86	Selection of Hepatitis B Virus (HBV) Vaccine Escape Mutants in HBV-Infected and HBV/HIV-Coinfected Patients Failing Antiretroviral Drugs With Anti-HBV Activity. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 279-282.	2.1	54
87	Outbreak of Syphilis, but Not of Acute Hepatitis C, Among HIV-Infected Homosexual Men in Madrid. <i>HIV Clinical Trials</i> , 2007, 8, 98-101.	2.0	20
88	Hepatitis C virus and human immunodeficiency virus: The Un-Won Battle. <i>Hepatology</i> , 2007, 46, 611-614.	7.3	6
89	Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4+ and CD8+ T-cell responses to hepatitis C virus. <i>Journal of Medical Virology</i> , 2007, 79, 503-510.	5.0	26
90	Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: Implications for HCV therapy in HCV/HIV-coinfected patients. <i>Journal of Infection</i> , 2007, 54, 173-179.	3.3	32

#	ARTICLE	IF	CITATIONS
91	Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2007, 14, 387-391.	2.0	35
92	Evolution of T-cell Responses to Hepatitis C Virus (HCV) during Pegylated Interferon plus Ribavirin treatment in HCV-Monoinfected and in HCV/HIV-Coinfected Patients. <i>Antiviral Therapy</i> , 2007, 12, 459-468.	1.0	9
93	Premature Treatment Discontinuation in HIV/HCV-Coinfected Patients Receiving Pegylated Interferon plus Weight-Based Ribavirin. <i>Antiviral Therapy</i> , 2007, 12, 469-476.	1.0	16
94	Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment. <i>Gastroenterology</i> , 2006, 131, 451-460.	1.3	361
95	Chronic Hepatitis C in HIV-Infected Patients: Those Who More Need Therapy are Those Who Respond Less. <i>Infectious Disorders - Drug Targets</i> , 2006, 6, 57-68.	0.8	1
96	Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002. <i>Journal of Viral Hepatitis</i> , 2006, 13, 851-857.	2.0	13
97	Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 177-182.	2.1	148
98	Impact of Antiretroviral Treatment-Related Toxicities on Hospital Admissions in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 825-829.	1.1	29
99	Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 401-405.	2.1	79
100	New paradigms in the management of HIV and hepatitis C virus coinfection. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 550-560.	3.1	15
101	Failure of Hepatitis C Therapy in HIV-Coinfected Drug Users Is Not Due to a Shift in Hepatitis C Virus Genotype. <i>Journal of Infectious Diseases</i> , 2005, 192, 1245-1248.	4.0	8
102	Complications in treating chronic hepatitis B in patients with HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2831-2842.	1.8	2
103	Impact of Ribavirin Exposure on Early Virological Response to Hepatitis C Therapy in HIV-Infected Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2005, 10, 657-662.	1.0	30
104	Response to Interferon-Based Therapies in HIV-Infected Patients with Chronic Hepatitis C Due to Genotype 4. <i>Antiviral Therapy</i> , 2005, 10, 167-170.	1.0	16
105	Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C: A European Collaborative Study. <i>Clinical Infectious Diseases</i> , 2004, 38, 128-133.	5.8	291
106	Hepatitis C Virus (HCV) Relapses after Anti-HCV Therapy Are More Frequent in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 351-353.	1.1	42
107	Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. <i>Journal of Viral Hepatitis</i> , 2004, 11, 2-17.	2.0	65
108	Management of Chronic Hepatitis C in Patients Co-Infected with HIV. <i>Drug Safety</i> , 2004, 27, 7-24.	3.2	13

#	ARTICLE	IF	CITATIONS
109	High Prevalence of Seropositivity to a Major Allergen of <i>Anisakis simplex</i> , <i>Ani s 1</i> , in Dyspeptic Patients. <i>Vaccine Journal</i> , 2004, 11, 115-118.	3.1	22
110	Hepatitis C Virus-Rna Clearance in HIV-Coinfected Patients with Chronic Hepatitis C Treated with Pegylated Interferon plus Ribavirin. <i>Antiviral Therapy</i> , 2004, 9, 505-509.	1.0	33
111	Long-Term Follow-Up of HIV-Infected Patients with Chronic Hepatitis C Virus Infection Treated with Interferon-Based Therapies. <i>Antiviral Therapy</i> , 2004, 9, 987-992.	1.0	63
112	Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon $\alpha$ -2b Plus Ribavirin. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 1083-1089.	1.1	25
113	Distribution of Hepatitis B Virus Genotypes in HIV-Infected Patients with Chronic Hepatitis B: Therapeutic Implications. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 657-659.	1.1	34
114	Pegylated IFN- $\alpha$ 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 2003, 17, 1023-1028.	2.2	183
115	Treatment of chronic hepatitis C virus infection. <i>Aids</i> , 2003, 17, 751-753.	2.2	29
116	Is Treatment Failure for Hepatitis C Virus Infection in HIV-Positive Drug Users Associated With a Shift in HCV Genotypes?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 32, 465-466.	2.1	1
117	Liver Biopsy in HIV-Infected Patients with Chronic Hepatitis C: Pros and Cons. <i>HIV Clinical Trials</i> , 2002, 3, 351-353.	2.0	6
118	Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. <i>HIV Clinical Trials</i> , 2002, 3, 99-114.	2.0	23
119	Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment. <i>Aids</i> , 2002, 16, 493-495.	2.2	15
120	Management of hepatitis C in HIV-infected persons. <i>Antiviral Research</i> , 2001, 52, 189-198.	4.1	28
121	Increasing Impact of Chronic Viral Hepatitis on Hospital Admissions and Mortality among HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1467-1471.	1.1	197
122	Re: Garcia-Samaniego et al.-Hepatocellular carcinoma in patients with HCV-HIV coinfection. <i>American Journal of Gastroenterology</i> , 2001, 96, 3441-3441.	0.4	1
123	Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2001, 96, 179-183.	0.4	215
124	Mortality Due to Chronic Viral Liver Disease among Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2001, 33, 1793-1795.	5.8	46
125	Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. <i>Journal of Viral Hepatitis</i> , 2000, 7, 403-408.	2.0	34
126	Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 212.	2.2	61



#	ARTICLE	IF	CITATIONS
127	Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 2000, 14, 2409-2410.	2.2	8
128	Interferon Plus Ribavirin in HIV-Infected Patients With Chronic Hepatitis C. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 22, 308.	2.1	8
129	Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. <i>European Journal of Epidemiology</i> , 1999, 15, 1-4.	5.7	158
130	Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. <i>Journal of Hepatology</i> , 1999, 31, 119-123.	3.7	61
131	Management of chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 1999, 13, 539-546.	2.2	90
132	Interferon Plus Ribavirin in HIV-Infected Patients With Chronic Hepatitis C. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 22, 308.	2.1	21
133	Lack of benefit or protease inhibitors on HCV viremia in HIV- infected patients. <i>Journal of Hepatology</i> , 1998, 28, 526-527.	3.7	52
134	Hepatotoxicity after introduction of highly active antiretroviral therapy. <i>Aids</i> , 1998, 12, 1256.	2.2	180
135	Co-infection with several HCV genotypes enhances liver damage in patients with chronic hepatitis C. <i>Journal of Infection</i> , 1997, 35, 202-203.	3.3	1
136	A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. <i>Journal of Infection</i> , 1997, 35, 225-230.	3.3	15
137	Hepatitis C viraemia in HIV-infected patients. <i>Aids</i> , 1996, 10, 922.	2.2	8
138	Circulating Hepatitis C Virus Genotypes in Spain. <i>Vox Sanguinis</i> , 1996, 70, 180-181.	1.5	10
139	Interferon $\alpha$ for the Treatment of Chronic Hepatitis C in Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1996, 23, 585-591.	5.8	187